[CAS NO. 404009-46-7] AMA-37
PRODUCTS SPECIFICATIONS [404009-46-7]
DESCRIPTION [404009-46-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 283.32 |
| Molecular Formula | C17H17NO3 |
| SMILES | O=C(C1=CC=C(N2CCOCC2)C=C1O)C3=CC=CC=C3 |
Summary
IC50 & Target
IC50: 0.27 μM (DNA-PK) [1] .
In Vitro
AMA-37 inhbits PI3K poorly
[2]
.
AMA-37 (20 μM) reduces the ability of UCN-01, isogranulatimide, and debromohymenialdesine, but not caffeine, to overcome G2 arrest (ρ < 0.05)
[3]
.
Inhibition of DNA-PK with AMA37 leads to radiosensitization
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 352.96 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.5296 mL | 17.6479 mL | 35.2958 mL |
| 5 mM | 0.7059 mL | 3.5296 mL | 7.0592 mL |
| 10 mM | 0.3530 mL | 1.7648 mL | 3.5296 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution
References
- [1] Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.
- [2] Zachary A Knight, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem. 2004 Sep 1;12(17):4749-59.
- [3] Christopher M Sturgeon, et al. Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Mol Cancer Ther. 2006 Apr;5(4):885-92.
